Multi-kinase inhibitors targeting the MAPK pathway, such as Vermurafenib (BRAF) and Selumetinib (MEK) are under study for advanced thyroid cancers, though none of them have yet been approved by the FDA. Here, MAP2K7 is linked to thyroid gland carcinoma.